SeraFILE™ generates alternate conformers in vitro. Such conformers may arise from discrete docking changes in the polypeptide chain, or through dissociation of positive or negative regulating factors, or some combination of the two. In all cases, the capability to exploit enzymatic variants and sub-states provides a new drug development strategy. Rather than blocking the activation of inactive conformers- the conventional drug discovery route, the ProFACT paradigm would promote deactivation from active states.

The presumed advantages are that the active conformer is more specific to disease than the inactive conformer, and that its lower stoichiometry would translate to lower dosages and lower toxicity. Unique and proprietary to ProFACT, these combined deliverables will provide an exceptional new approach to accelerate drugs to market. Rational Proteome Prospecting ™ can be used to isolate or purify important drug targets. Conformerics™ will integrate these targets within drug screening assays.